SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the presentation of data from a pre-clinical study demonstrating that the administration of SCV-07 in conjunction with the BCG tuberculosis (TB) vaccine resulted in a significantly superior protective effect against Mycobacterium tuberculosis, the bacteria that cause TB, compared with the administration of the BCG vaccine alone. Dr. Todd M. Lasco, Director of Microbiology at Mycos Research, LLC, presented these data today at the second international conference on TB Vaccines for the World in Vienna, Austria.
